Dec 15th PR, "Some of youbeen>here>to>see>our>operations>I>invite all of you to do the same. Please email me for documentation of any item mentioned in this letter. I look forward to keeping you current on all developments, but more importantly posting audited revenue and earnings."
Medical Marijuana
Sannabis, our joint venture, introduced a newly designed product line that will enhance sales. Sannabis is a medical marijuana pioneer in Colombia operating in an area notorious for growing high quality marijuana all year round. Our indigenous partners who are totally opposed to illegal drug trafficking and legally grow 100% organic, all natural medical marijuana on their reservation, process it onsite into a variety of topical and oral products that are sold by distributors throughout Colombia. Not only are we providing for the farmers but we create value added jobs in product development to the community. The Colombian military contacted us to establish alternative crops for other indigenous regions of Colombia in post conflict zones. This will be documented by reporters and film crews and is expected to garner significant international attention. Infomercials will be filmed next month with retired professional athletes promoting our all natural CBD products for the U.S. market and medical marijuana products for the Colombia market. International interest has sparked and we're gearing up to manufacture dozens of products for international buyers.
FDA Applications
I'm meeting with Dr. Stanley Satz of Advanced Imaging Projects (AiP) today to finalize our joint venture agreements to file for an orphan drug designation with the Food and Drug Administration (FDA). We've identified the indications we will file for and they'll be detailed in an 8K filing along with file numbers.
Some of you have been here to see our operations, I invite all of you to do the same. Please email me for documentation of any item mentioned in this letter. I look forward to keeping you current on all developments, but more importantly posting audited revenue and earnings.
